{"id":"W3088837832","doi":"10.1016/j.annonc.2020.08.1088","title":"973TiP LEAP-010: Phase III study of first-line pembrolizumab with or without lenvatinib in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Merck Sharp and Dohme","keywords":"Pembrolizumab; Medicine; Lenvatinib; Internal medicine; Tolerability; Head and neck squamous-cell carcinoma; Oncology; Adverse effect; Placebo; Phases of clinical research; Head and neck cancer; Clinical trial; Immunotherapy; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009566959,0.001066478,0.001730218,0.0003875738,0.0003417854,0.001417434,0.001148309,0.001108577,0.006590249],"category_scores_gemma":[0.0004921157,0.0006108455,0.001512424,0.0004718267,0.0007556616,0.001010314,0.0003453409,0.00420237,0.001945222],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001077156,"about_ca_system_score_gemma":0.001826395,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001734664,"about_ca_topic_score_gemma":0.004926962,"domain_scores_codex":[0.9997552,0.00008281916,0.0000108338,0.00004896065,0.00002596417,0.00007620713],"domain_scores_gemma":[0.9997057,0.00003820314,0.00003623457,0.00002190502,0.0000205259,0.0001773769],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6638371,0.05493708,0.008037352,0.001836949,0.003094354,0.0003115265,0.0003267813,0.003409396,0.05253647,0.0006140413,0.01049789,0.200561],"study_design_scores_gemma":[0.6392033,0.3273677,0.01700646,0.00007960278,0.0014273,0.0004595149,0.0001318198,0.00230692,0.005764076,0.0002748535,0.005922037,0.00005636614],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9878702,0.002992639,0.0004320682,0.0006159252,0.0002443111,0.001413063,0.002240103,0.0002022237,0.003989497],"genre_scores_gemma":[0.9802388,0.003288877,0.00140753,0.001349253,0.0001840628,0.001847635,0.004772045,0.00006135709,0.006850534],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006590249,"threshold_uncertainty_score":0.02204657,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09192149957931987,"score_gpt":0.3708962029273843,"score_spread":0.2789747033480644,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}